Analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX – Get Free Report) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $2.50 target price on shares of VolitionRx in a report on Wednesday, March 27th.
Get Our Latest Stock Report on VNRX
VolitionRx Trading Up 1.0 %
VolitionRx (NYSE:VNRX – Get Free Report) last released its earnings results on Monday, March 25th. The company reported ($0.11) earnings per share (EPS) for the quarter. The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.50 million. On average, sell-side analysts predict that VolitionRx will post -0.4 EPS for the current fiscal year.
Hedge Funds Weigh In On VolitionRx
An institutional investor recently raised its position in VolitionRx stock. Vanguard Group Inc. lifted its position in shares of VolitionRx Limited (NYSE:VNRX – Free Report) by 4.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 542,444 shares of the company’s stock after acquiring an additional 22,046 shares during the quarter. Vanguard Group Inc. owned 0.69% of VolitionRx worth $374,000 as of its most recent SEC filing. 8.09% of the stock is currently owned by institutional investors.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Read More
- Five stocks we like better than VolitionRx
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Comprehensive Analysis of PayPal Stock
- What is a Death Cross in Stocks?
- Intuitive Surgical Stock Can Trend Much Higher This Year
- What Investors Need to Know About Upcoming IPOs
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.